Benzinga · Aug 13, 2026
Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.29) per share. This is a 30.95 percent increase over losses of $(0.42) per share from the same period last year.
PU
NASDAQ · PULM
Pulmatrix, Inc.
Healthcare · Biotechnology
$1.54
Up+$0.03 (+1.99%)
Updated Aug 15, 2026, 11:20 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 14.43M
- P/E ratio
- -2.32
- Dividend yield
- 0.00%
- 52-week range
- $1.16 – $2.49
- Volume
- 17.77K
- Avg. volume
- 11.96K
Price performance
PULM price history
1M range · 20 trading sessions · Daily adjusted prices
PULM closed at $1.54 after 20 trading sessions, down 8.88% for the selected period.
- Last close
- $1.54
- Period change
- -8.88%
- Period low
- $1.51
- Period high
- $1.77
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $1.51 | $1.57 | $1.50 | $1.54 | 17.77K |
| Aug 13, 2026 | $1.45 | $1.60 | $1.45 | $1.51 | 20.61K |
| Aug 11, 2026 | $1.59 | $1.60 | $1.58 | $1.60 | 5.76K |
| Aug 10, 2026 | $1.64 | $1.64 | $1.56 | $1.57 | 9.29K |
| Aug 7, 2026 | $1.675 | $1.68 | $1.66 | $1.66 | 1.38K |
| Aug 6, 2026 | $1.68 | $1.68 | $1.66 | $1.66 | 1.55K |
| Aug 5, 2026 | $1.66 | $1.7114 | $1.65 | $1.65 | 3.98K |
| Aug 4, 2026 | $1.6401 | $1.72 | $1.64 | $1.66 | 17.33K |
| Aug 3, 2026 | $1.69 | $1.75 | $1.67 | $1.74 | 7.55K |
| Jul 31, 2026 | $1.685 | $1.74 | $1.63 | $1.74 | 16.36K |
| Jul 30, 2026 | $1.66 | $1.7037 | $1.64 | $1.70 | 12.17K |
| Jul 29, 2026 | $1.73 | $1.75 | $1.665 | $1.67 | 17.68K |
| Jul 28, 2026 | $1.68 | $1.72 | $1.68 | $1.68 | 11.84K |
| Jul 27, 2026 | $1.635 | $1.76 | $1.635 | $1.73 | 9.13K |
| Jul 24, 2026 | $1.78 | $1.78 | $1.6476 | $1.65 | 14.87K |
| Jul 23, 2026 | $1.67 | $1.80 | $1.6651 | $1.77 | 20.57K |
| Jul 22, 2026 | $1.625 | $1.70 | $1.625 | $1.69 | 3.62K |
| Jul 21, 2026 | $1.65 | $1.70 | $1.65 | $1.70 | 4.1K |
| Jul 20, 2026 | $1.64 | $1.68 | $1.62 | $1.68 | 12.77K |
| Jul 17, 2026 | $1.60 | $1.69 | $1.60 | $1.69 | 20.75K |
Latest PULM news
The latest Smart Investors Daily articles mentioning PULM.
Stock researchCompany · Overview
PULM research
Overview
Company profile and research snapshot.
Company profile
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 15, 2023 | HC Wainwright & Co. | Buy | — |
| May 15, 2023 | HC Wainwright & Co. | Buy | — |
| Feb 7, 2023 | HC Wainwright & Co. | Buy | — |
| Mar 30, 2022 | HC Wainwright & Co. | Buy | — |
| Apr 13, 2021 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 26, 2026
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · Mar 26, 2026
Pulmatrix shares are trading lower after the company announced it will acquire Eos, a developer of novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases.
Benzinga · Mar 26, 2026
Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
